综合分析显示,关键的西斯普拉丁耐药调节剂E2F7有助于肺腺癌瘤的瘤进展和转移
Xiaomin Mao1, Shumin Xu2, Huan Wang2
1Department of Nursing, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Yiwu, 322000, China.
Cancer cell international
|May 17, 2024
概括
这项研究确定了E2F7和FAM83A作为预测肺腺癌 (LUAD) 中西斯普拉丁耐药性的关键基因. 向E2F7通过抑制LUAD生长和进展,显示出治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 药物耐药性,特别是对西斯的耐药性,是肺腺癌 (LUAD) 治疗的一个主要挑战,导致治疗失败.
- 识别与西斯普拉丁耐药性相关的特定基因对于开发个性化治疗策略至关重要.
- E2F7和FAM83A成为LUAD对西斯普拉丁耐药性的重要遗传标志物.
研究的目的:
- 在LUAD中识别与西斯普拉丁耐药性相关的基因.
- 使用关键已识别的基因开发LUAD的预后模型.
- 调查在LUAD中准E2F7的治疗潜力.
主要方法:
- 对抗西斯普拉丁的LUAD细胞的转录组数据分析.
- 单变量和多变量回归分析以确定预后基因 (E2F7,FAM83A).
- 在体外测试 (细胞计数套件8,Transwell,流动细胞计量) 和西部抹杀以评估E2F7功能和信号通路 (AKT/mTOR).
主要成果:
- 鉴定出E2F7和FAM83A是LUAD中对西斯普拉丁耐药性的关键基因.
- 基于E2F7和FAM83A的预后模型展示了诊断和复发风险评估能力.
- 抑制E2F7降低了LUAD细胞的增殖,迁移,入侵和亡的增加,在体内观察到类似的效应.
结论:
- 使用E2F7和FAM83A的预后模型可靠地预测LUAD中的免疫治疗成功.
- E2F7通过通过AKT/mTOR途径抑制LUAD生长和进展,显示出治疗潜力.
- 这种基于基因的模型支持在LUAD治疗中个性化医疗方法.
相关概念视频
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


